bioAffinity Technologies, Inc.
BIAFW- Exchange
- Nasdaq
- Industry
- Services-Commercial Physical & Biological Research
- SEC CIK
- 0001712762
No open-market purchases or sales by bioAffinity Technologies, Inc. insiders were filed in the last 90 days; 4 institutions reported holding it in 13F filings for Q2 2026, worth $18.1K in total; no superinvestor holds it.
Other share classesBIAF
Q3 2022 vs. Q2 2022
How the institutions holding bioAffinity Technologies, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 0 | 6 | +6 |
| Shares | 0 | 298.9K | +298.9K |
| Value | $0 | $137.0K | +$137.0K |
New holders (6)
Institutions that held bioAffinity Technologies, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Armistice Capital, LLC | 204,082 | $72.0K | 0.00% |
| Boothbay Fund Management, LLC | 12,500 | $36.0K | 0.00% |
| Susquehanna International Group, LLP | 26,185 | $9.00K | 0.00% |
| Clear Street LLC | 25,000 | $9.00K | 0.00% |
| Warberg Asset Management LLC | 19,426 | $7.00K | 0.00% |
| UBS Group AG | 11,712 | $4.00K | 0.00% |
Sold out (0)
Institutions that held bioAffinity Technologies, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
None.